ClinicalTrials.gg
Not yet recruitingNCT07943377Updated Nov 17, 2026

Safety, Tolerability, and Pharmacokinetics of Supratherapeutic Doses of ALG-000184 (Parts A and B) and the Absorption, Metabolism, Excretion, and Absolute Bioavailability of ALG-001075 Following a Single Oral Dose of [14C]ALG-000184 and a Single Intravenous Dose of [13C7,15N1]ALG-001075 (Part C)

A Phase 1 interventional study of ALG-000184 and Placebo in Healthy Participants, sponsored by Aligos Therapeutics. Not yet recruiting at 1 site in United States. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by Aligos Therapeutics · Phase 1, Interventional, and Treatment

Updated Nov 17, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
55
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Study summary

A Phase 1 trial of ALG-000184 in healthy participants to assess the safety and tolerability of single and multiple (if applicable) oral doses of ALG-000184 (Part A and B) and ALG-001075 Following a Single Oral Dose of [14C]ALG-000184 and a Single Intravenous Dose of [13C7,15N1]ALG-001075 (Part C)

02

Conditions studied

  • Healthy Participants
03

In context

Lead sponsor

Aligos Therapeutics is the lead sponsor of 16 studies on the registry; 1 is open to participants now.

Of its 7 completed or terminated interventional studies of FDA-regulated products, 2 (29%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Inclusion Criteria: Key Inclusion Criteria

  1. Parts A and B only: Male or female between 18 and 60 years of age
  2. Part C only: Males between 18 and 55 years of age.
  3. between 18.0 kg/m2 and 32.0 kg/m2
  4. In good health, as determined by no findings from medical history, 12-lead and vital signs measurements, and clinical laboratory assessments.
  5. Part C only: History of a minimum of 1 bowel movement per day.

Exclusion Criteria: Key Exclusion Criteria:

  1. Significant history or clinical manifestation of any metabolic, allergic, dermatological, hepatic, renal, hematological, pulmonary, cardiovascular, gastrointestinal, neurological, respiratory, endocrine, or psychiatric disorder, as determined by the investigator (or designee).
  2. History of significant , intolerance, or allergy to any drug compound, food, or other substance, as determined by the investigator (or designee).
  3. History of stomach or intestinal surgery or resection that would potentially alter absorption and/or excretion of orally administered drugs.
  4. Confirmed systolic blood pressure >140 or \<90 mmHg, diastolic blood pressure >90 or \<50 mmHg, or pulse rate >100 or \<40 beats per minute.
  5. Positive hepatitis panel and/or positive test.
  6. Parts A and B only: Any of the following at screening or check-in:

    1. >450 ms in males or >470 ms in females
    2. QRS duration >120 ms
    3. PR interval >210 ms
    4. findings which would make QTc measurements difficult or QTc data uninterpretable
  7. Administration of any vaccine within 30 days prior to dosing.
  8. Use or intend to use any prescription medications/products, other than hormone replacement therapy, within 14 days prior to dosing
  9. Alcohol consumption of >21 units per week for males and >14 units per week for females, as applicable.
  10. Positive urine drug screen at screening or positive alcohol test result or positive urine drug screen at check-in.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
55 participants (estimated)

Study arms

  • Experimental
    ALG-000184

    Oral tablet(s) of placebo in HV participants once daily for up to 10 days

    Drug: ALG-000184

  • Placebo comparator
    Placebo

    Oral tablet(s) of placebo in HV participants once daily for up to 10 days

    Drug: Placebo

  • Other
    [14C]ALG-000184

    Radiation: [14C]ALG-000184 · Radiation: [13C7,15N1]ALG-001075

Interventions

  • DrugALG-000184

    Single or multiple doses of ALG-000184

  • DrugPlacebo

    Single or multiple doses of Placebo

  • Radiation[14C]ALG-000184

    Single oral dose of \[14C\]ALG-000184

  • Radiation[13C7,15N1]ALG-001075

    Single micodose of \[13C7,15N1\]ALG-001075 with combination of \[14C\]ALG-000184

06

What researchers measure

Primary outcomes

  1. Safety and Tolerability (Part A and B)

    Number of participants with Incidence and severity of adverse events, 12-lead electrocardiogram parameters, and abnormal clinical laboratory results

    Time frame: From enrollment to end of treatment at 10 days

  2. PK Parameters (Part A and B)

    PK parameters of ALG-001075 and ALG-000302, including AUC0-∞

    Time frame: From enrollment to end of treatment at 10 days

  3. PK Parameters (Part A and B)

    PK parameters of ALG-001075 and ALG-000302, including AUC0-tlast

    Time frame: From enrollment to end of treatment at 10 days

  4. PK Parameters (Part A and B)

    PK parameters of ALG-001075 and ALG-000302, including AUC0-τ

    Time frame: From enrollment to end of treatment at 10 days

  5. PK Parameters (Part A and B)

    PK parameters of ALG-001075 and ALG-000302, including Cmax

    Time frame: From enrollment to end of treatment at 10 days

  6. PK Parameters (Part A and B)

    PK parameters of ALG-001075 and ALG-000302, including tmax t1/2

    Time frame: From enrollment to end of treatment at 10 days

  7. PK Parameters (Part A and B)

    PK parameters of ALG-001075 and ALG-000302, including ARAUC

    Time frame: From enrollment to end of treatment at 10 days

  8. Total radioactivity recovery (fet1-t2) in urine and feces (Part C)

    determine the routes, rates of elimination, and mass balance of total radioactivity following a single oral dose of \[14C\]ALG-000184

    Time frame: From enrollment to end of treatment at 10 days

  9. Metabolic profiles of ALG-000184 (Part C)

    Determine, where possible, the metabolite profiles in plasma, urine, and feces following administration of \[14C\]ALG-000184

    Time frame: From enrollment to end of treatment at 10 days

  10. Identification of ALG-000184 (Part C)

    Determine, where possible, the chemical structure of major metabolites in plasma, urine, and feces following administration of \[14C\]ALG-000184

    Time frame: From enrollment to end of treatment at 10 days

  11. Bioavailability of ALG-001075 (Part C)

    Determine the absolute bioavailability of ALG-001075 following oral administration of \[14C\]ALG-000184 relative to IV administration of \[13C7,15N1\]ALG-001075

    Time frame: From enrollment to end of treatment at 10 days

  12. PK parameters (Part C)

    PK parameters for ALG-001075 and \[13C7,15N1\]ALG-001075 in plasma and total radioactivity in plasma and whole blood including AUC0-∞

    Time frame: From enrollment to end of treatment at 10 days

  13. PK parameters (Part C)

    PK parameters for ALG-001075 and \[13C7,15N1\]ALG-001075 in plasma and total radioactivity in plasma and whole blood including AUC0-tlast

    Time frame: From enrollment to end of treatment at 10 days

  14. PK parameters (Part C)

    PK parameters for ALG-001075 and \[13C7,15N1\]ALG-001075 in plasma and total radioactivity in plasma and whole blood including Cmax

    Time frame: From enrollment to end of treatment at 10 days

  15. PK parameters (Part C)

    PK parameters for ALG-001075 and \[13C7,15N1\]ALG-001075 in plasma and total radioactivity in plasma and whole blood including tmax

    Time frame: From enrollment to end of treatment at 10 days

  16. PK parameters (Part C)

    PK parameters for ALG-001075 and \[13C7,15N1\]ALG-001075 in plasma and total radioactivity in plasma and whole blood including t1/2

    Time frame: From enrollment to end of treatment at 10 days

Secondary outcomes

  1. QTc (Part A and B)

    Evaluate the effect of single and multiple (if applicable) oral doses of ALG-000184 on QTc in healthy participants

    Time frame: From enrollment to end of treatment at 10 days

  2. Safety and Tolerability (Part C)

    Number of participants with Incidence and severity of adverse events, 12-lead electrocardiogram parameters, and abnormal clinical laboratory results

    Time frame: From enrollment to end of treatment at 10 days

07

Study locations

1 site
  • Aligos Investigational Site
    Madison, Wisconsin 53704, United States
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Dec 2026; primary completion for Aug 2027, 7 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 11, 2026
First posted
Nov 17, 2026
StartEst.
Dec 14, 2026
Primary completionEst.
Aug 6, 2027
CompletionEst.
Oct 1, 2027
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 17, 2026
Show all 1 update
  1. Nov 17, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07943377
Lead sponsor
Aligos Therapeutics
Responsible party
Sponsor
First posted
Nov 17, 2026
Start date
Dec 14, 2026 (estimated)
Primary completion
Aug 6, 2027 (estimated)
Completion
Oct 1, 2027 (estimated)
Last update
Nov 17, 2026

Study contacts

Aligos Therapeutics
Contact
info@aligos.com
800-466-6059

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion